REGENXBIO develops gene therapies that use AAV vectors to deliver working genes into cells to treat disease. It last closed at $7.24 on Nov 17, down 1.09% on the day. The average 12-month price target from 3 analysts is $24.00 (+231.5% from the last close), with a high of $29.00 and a low of $21.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Each firm's latest rating on RGNX in the past 90 days
Average 12-month target
$24.00
▲ 231.5% upside
Based on 3 analysts who set a price target on RGNX in the past 90 days. The average target is $24.00, with a high of $29.00 and a low of $21.00, compared with the last close of $7.24.
Low $21.00Avg $24.00High $29.00
Blue marker: last close $7.24
Highest target$29.00
Average target$24.00
Lowest target$21.00
Latest rating changes
MizuhoInitiated
Oct 5Buy$22
HC Wainwright & Co.Target lowered
Aug 25Buy$23 → $21
BairdTarget lowered
Aug 25Buy$32 → $29
HC Wainwright & Co.Target lowered
Aug 10Buy$26 → $23
HC Wainwright & Co.Reiterated
Jun 24Buy$26
Date
Firm
Action
Rating
Price target
Oct 5
Mizuho
Initiated
Buy
$22
Aug 25
HC Wainwright & Co.
Target lowered
Buy
$23 → $21
Aug 25
Baird
Target lowered
Buy
$32 → $29
Aug 10
HC Wainwright & Co.
Target lowered
Buy
$26 → $23
Jun 24
HC Wainwright & Co.
Reiterated
Buy
$26
Loading…
Technical Analysis
RGNX · as of the Nov 17 close · updated after every close
Moving sideways
The stock is 2% below its 20 day and 5% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the swing low (Oct 7) at $7.20, and the nearest resistance the swing high (Jun 1) at $7.32.
Short trendNeutral
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.1%/day
Key levels
$16.1952 week high+123.6%
$9.26100 day average+27.9%
$8.84200 day average+22.1%
$7.5950 day average+4.8%
$7.54Pivot R1+4.1%
$7.4020 day average+2.2%
$7.32Swing high (Jun 1)+1.1%
$7.24Last close
$7.20Swing low (Oct 7)−0.6%
$7.19Pivot−0.7%
$6.89Pivot S1−4.8%
$5.4652 week low−24.6%
Indicators
RSI (14)
45.82
Middle of its range
Neutral
MACD
0.01
Above its signal line
Bullish
Stochastic
34.2
Middle of its range
Neutral
ADX (14)
13.0
No clear trend
Williams %R
-80.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-40.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−5.1%
Change over 10 sessions
Bearish
ATR (14)
$0.58
Typical daily range, 8.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNormal
VolatilityNormal, 20.7%/day
Key levels
$16.1952 week high+123.6%
$9.26100 day average+27.9%
$8.84200 day average+22.1%
$7.5950 day average+4.8%
$7.54Pivot R1+4.1%
$7.4020 day average+2.2%
$7.32Swing high (Jun 1)+1.1%
$7.24Last close
$7.20Swing low (Oct 7)−0.6%
$7.19Pivot−0.7%
$6.89Pivot S1−4.8%
$5.4652 week low−24.6%
Indicators
RSI (14)
43.08
Middle of its range
Neutral
MACD
-0.63
Below its signal line
Bearish
Stochastic
18.5
Near the bottom of its range
Oversold
ADX (14)
12.4
No clear trend
Williams %R
-86.1
Oversold below −80, overbought above −20
Oversold
CCI (20)
-75.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−15.1%
Change over 10 sessions
Bearish
ATR (14)
$1.50
Typical daily range, 20.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for RGNX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RGNX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RGNX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RGNX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RGNX is in one of them and how their past RGNX trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About REGENXBIO
REGENXBIO is a biotechnology company based in Rockville, Maryland, that develops gene therapies. Its treatments use modified viruses called AAV vectors, which are designed to deliver working genes into cells. The company's own pipeline targets eye, muscle and nervous system diseases. It also licenses its vector platform to drugmakers such as AbbVie and Novartis, which develop treatments for their own patients.